Conference Correspondent

JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data. Read More ›

TGFβ is a cytokine that enhances myelofibrosis disease progression. AVID200, a TGFβ1/3 inhibitor, may provide clinical benefit manifesting as improved platelet counts in patients with myelofibrosis who have thrombocytopenia. Read More ›

Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib. Read More ›

Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed FLT3^mut+ AML ineligible for intensive induction chemotherapy. Read More ›

In a retrospective analysis, upfront liposomal daunorubicin/cytarabine treatment was shown to accord an overall survival advantage compared with HMA + venetoclax, which, however, did not extend to complete response rates and recurrence-free survival. Read More ›

Results from an ongoing first-in-human phase 1/2 study indicated that the FLT3/SYK inhibitor HM43239 yielded a favorable safety profile and encouraging antileukemic activity in patients with relapsed/refractory AML regardless of FLT3 mutation status. Read More ›

Findings from a retrospective analysis suggested that venetoclax plus hypomethylating agent plus an FLT3 inhibitor led to significant improvement in clinical outcomes, in older and unfit patients with FLT3-mutated AML. Read More ›

Patients with treated secondary AML and prior hypomethylating exposure derived significant clinical benefit from hypomethylating agents plus venetoclax therapy compared with chemotherapy-based approaches. Read More ›

Conditioning regimens for allo-HSCT includes either myeloablative conditioning or reduced-intensity conditioning. The use of fludarabine/busulfan appears to deliver better patient outcomes after transplant compared with other commonly used conditioning regimens. Read More ›

Clinical trials have demonstrated JAK2 inhibition with fedratinib effectively reduces spleen volume and improves symptoms in patients with myelofibrosis. It has yet to be determined whether spleen size before fedratinib therapy influences these effects. Read More ›